DPYD Genotyping and 5‑Fluorouracil (5‑FU) Dosing Guidelines

Epidemiology & Clinical Impact of DPYD Variants

• Approximately 4 % of patients screened for fluoropyrimidine therapy carry a DPYD variant that can affect drug metabolism. (National Comprehensive Cancer Network – NCCN) 1
• Treatment‑related mortality is markedly higher in DPYD variant carriers (≈ 2.3 % vs 0.1 % in wild‑type), representing a 23‑fold increased risk of death. (NCCN) 1

Guideline Recommendations for Dose Adjustment (CPIC)

• Intermediate metabolizers (heterozygous for decreased/no‑function DPYD variants):

• Poor metabolizers (homozygous loss‑of‑function variants):

Evidence Supporting Dose Reduction

• Prospective cohort of 2,038 patients (22 DPYD*2A carriers, 1.1 % prevalence) receiving dose‑reduced fluoropyrimidine showed:

• Prospective study of 85 patients (8 % of screened cohort) with the four most common DPYD variants received initial 25 % or 50 % dose reductions and demonstrated a reduced relative risk of severe fluoropyrimidine toxicity compared with historical cohorts. (NCCN) 1

Efficacy Outcomes with Dose Reduction

• Multicenter prospective matched study (156 DPYD variant carriers vs 775 wild‑type controls):

Testing Recommendations (NCCN)

• Universal pretreatment DPYD genotyping is not currently recommended because of uncertainty regarding the impact of dose adjustments on efficacy and the central role of fluoropyrimidines in colorectal cancer therapy. (NCCN) [2][3]
• Patients identified with DPYD variants may receive dose reductions or be offered non‑fluoropyrimidine regimens at the clinician’s discretion. (NCCN) 1

Emergency Management of Severe Fluoropyrimidine Toxicity

• Uridine triacetate is FDA‑approved for life‑threatening 5‑FU or capecitabine toxicity when administered within 96 hours of the last drug dose. (NCCN) [2][3]
• In clinical trials, 96 % of treated patients survived with rapid reversal of severe cardiac and neurologic toxicities. (NCCN) 3
• Mortality rises to 50 % when treatment is delayed beyond 96 hours, underscoring the importance of early administration. (NCCN) 3
• Cost of a treatment cycle is approximately $75,000. (NCCN) 1

Practical Considerations & Limitations

• CPIC dosing recommendations do not differentiate between IV bolus, continuous infusion 5‑FU, or oral capecitabine, despite differing pharmacokinetics. (CPIC) 2
• Known DPYD variants explain only 17‑59 % of phenotypic DPD deficiency, indicating that not all at‑risk patients will be identified by genotyping alone. (No citation ID – omitted)
• Efficacy may be compromised with dose reduction in carriers of the c.1236G>A variant, particularly in curative (adjuvant) settings where treatment intent is cure. (NCCN) [2][3]

DPYD Gene Testing for Capecitabine Therapy

Introduction to DPYD Gene Testing

• The National Comprehensive Cancer Network (NCCN) acknowledges that patients with DPYD variants could receive dose reductions or be offered non-fluoropyrimidine regimens 4, 5
• DPYD variants occur in approximately 4.1% of patients screened for fluoropyrimidine therapy 4, 5

FDA Contraindication and Risk Profile

• Treatment-related mortality is 2.3% in patients with known DPYD variants versus only 0.1% in those without variants, representing a 25.6-fold increased risk of treatment-related death 4, 5

Current Guideline Recommendations

• The NCCN does not currently support universal pretreatment DPYD genotyping, but recognizes that patients with DPYD variants could receive dose reductions or be offered non-fluoropyrimidine regimens 6, 7
• The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides standardized dosing recommendations based on DPYD genotype 4
• For intermediate metabolizers (heterozygous for DPYD decreased/no function variants): reduce starting dose by 25-50% depending on the specific variant 4
• For poor metabolizers (homozygous variants): avoid fluoropyrimidines entirely 4, 8

Evidence Supporting DPYD Testing

• In a prospective study of 2,038 patients screened, 22 patients (1.1%) with the DPYD*2A variant received dose-reduced fluoropyrimidine, resulting in grade ≥3 toxicity of 28% versus 73% in historic controls (P <0.001) 4, 5, 7
• Zero treatment-related deaths occurred in the dose-reduced group compared to 10% mortality in the historical control group 4, 5, 7

Efficacy Considerations with Dose Reduction

• For most DPYD variant carriers, progression-free survival and overall survival are not significantly affected by lower fluoropyrimidine doses 8
• Efficacy concerns may be more significant in the adjuvant setting than in metastatic disease 4, 8

Specific Variants to Test

• DPYD*2A (c.1905+1G>A): Most well-established pathogenic variant, associated with severe toxicity 4, 5, 7

Clinical Implementation Algorithm

• Consider DPYD genotyping for at minimum the 4 most common variants (DPYD2A, 13, D949V, HapB3), particularly in patients where severe toxicity would be catastrophic or in those receiving adjuvant therapy where efficacy is paramount 4, 5, 8
• If testing is not performed, monitor extremely closely for early signs of severe toxicity including bone marrow suppression, mucositis, palmar-plantar syndrome, and diarrhea 8

Common Pitfalls

• Do not assume all patients with DPYD variants will experience toxicity - there is heterogeneity in clinical presentation, but the risk is substantially elevated 4, 5
• Be aware that the CPIC dosing recommendations do not distinguish between intravenous bolus, infusional 5-FU, or oral capecitabine, despite different pharmacokinetics 4